Pişkin Özcan, Küçükosman Gamze, Altun Deniz Utku, Çimencan Murat, Özen Banu, Aydın Bengü Gülhan, Okyay Rahşan Dilek, Ayoğlu Hilal, Turan Işıl Özkoçak
Department of Anesthesiology and Reanimation, School of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
Department of Anesthesiology and Reanimation, School of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
Braz J Anesthesiol. 2016 Jul-Aug;66(4):376-82. doi: 10.1016/j.bjane.2014.10.003. Epub 2015 May 23.
Sugammadex is the first selective relaxant binding agent. When compared with neostigmine, following sugammadex administration patients wake earlier and have shorter recovery times. In this study, we hypothesized that fast and clear awakening in patients undergoing general anesthesia has positive effects on cognitive functions in the early period after operation.
Approved by the local ethical committee, 128 patients were enrolled in this randomized, prospective, controlled, double-blind study. Patients were allocated to either Sugammadex group (Group S) or the Neostigmine group (Group N). The primary outcome of the study was early postoperative cognitive recovery as measured by the Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). After baseline assessment 12-24h before the operation. After the operation, when the Modified Aldrete Recovery Score was ≥9 the MMSE and 1h later the MoCA tests were repeated.
Although there was a reduction in MoCA and MMSE scores in both Group S and Group N between preoperative and postoperative scores, there was no statistically significant difference in the slopes (p>0.05). The time to reach TOF 0.9 was 2.19min in Group S and 6.47min in Group N (p<0.0001). Recovery time was 8.26min in Group S and 16.93min in Group N (p<0.0001).
We showed that the surgical procedure and/or accompanying anesthetic procedure may cause a temporary or permanent regression in cognitive function in the early postoperative period. However, better cognitive performance could not be proved in the Sugammadex compared to the Neostigmine.
舒更葡糖钠是首个选择性肌松药结合剂。与新斯的明相比,给予舒更葡糖钠后患者苏醒更早,恢复时间更短。在本研究中,我们假设全身麻醉患者的快速且清晰的苏醒对术后早期认知功能有积极影响。
经当地伦理委员会批准,128例患者纳入本随机、前瞻性、对照、双盲研究。患者被分配至舒更葡糖钠组(S组)或新斯的明组(N组)。本研究的主要结局是通过蒙特利尔认知评估量表(MoCA)和简易精神状态检查表(MMSE)测量的术后早期认知恢复情况。在手术前12 - 24小时进行基线评估。术后,当改良Aldrete恢复评分≥9分时重复进行MMSE测试,1小时后重复进行MoCA测试。
虽然S组和N组术前与术后的MoCA和MMSE评分均有所降低,但斜率无统计学显著差异(p>0.05)。S组达到强直后计数(TOF)0.9的时间为2.19分钟,N组为6.47分钟(p<0.0001)。S组恢复时间为8.26分钟,N组为16.93分钟(p<0.0001)。
我们表明手术操作和/或伴随的麻醉操作可能在术后早期导致认知功能暂时或永久性减退。然而,与新斯的明相比,舒更葡糖钠并未显示出更好的认知表现。